ReproCELL Incorporated (4978) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
12 Nov, 2026Executive summary
H1 FY2027 revenue rose 18.7% YoY to ¥1,156m; operating loss narrowed to ¥497m, ordinary loss to ¥318m and net loss to ¥319m.
Research support delivered segment profit, while medical activities remained loss-making; full-year guidance was unchanged.
Financial highlights
Revenue was ¥1,156m vs ¥974m YoY; operating loss ¥497m vs ¥546m, ordinary loss ¥318m vs ¥483m and net loss ¥319m vs ¥486m.
Comprehensive income was ¥319m, compared with a ¥309m comprehensive loss in the prior-year interim period, including ¥649m in other securities valuation gains.
H1 EPS was -¥3.24 vs -¥5.14 YoY; FY forecast EPS is -¥4.47, based on a projected weighted-average 102.469m shares.
Outlook and guidance
FY2027 guidance remains revenue ¥2,629m, operating loss ¥630m, ordinary loss ¥458m and net loss ¥458m; no revisions were made.
Full-year EPS forecast reflects share-count increases from equity placements; further warrant exercises are excluded from the estimate.
Latest events from ReproCELL Incorporated
- Net sales up 14.9% YoY, losses narrowed, and new capital raised for clinical trials and R&D.4978
Q1 2027 - Sales and profits declined sharply, with losses deepening and forecasts revised downward.4978Q3 2026
- Revenue declined 26% with deepening losses, but cash and equity remain strong.4978Q2 2026
- Revenue fell 23% and losses widened, but cash reserves and R&D investments remain robust.4978Q1 2026
- Revenue and net income increased, with strong growth in iPS and biotherapeutics segments.4978Q2 2025
- Revenue up 22.7% and net income positive, but losses expected next year as R&D ramps up.4978Q4 2025
- Revenue up 16.4% with narrowed losses; research support drives growth, medical profit falls.4978Q3 2025